ArticleAmerican journal of translational research2021
Changes and significance of serum CXCL-16, GDF-15, PLA-2 levels in patients with cerebral infarction.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- A systematic review of the neuroprotective role and biomarker potential of GDF15 in neurodegeneration.Frontiers in immunology · 2024Pooled it
- Special Issue "Alcohol and Inflammation".International journal of molecular sciences · 2026Article
- Growth differentiation factor 15: from stress response to clinical utility in chronic liver diseases.Journal of gastroenterology · 2026Review
- The Crosstalk Between Ferritinophagy and Ferroptosis in Ischemic Stroke: Regulatory Mechanisms and Therapeutic Implications.Cellular and molecular neurobiology · 2025Review
- Molecular mechanisms of programmed cell death and potential targeted pharmacotherapy in ischemic stroke (Review).International journal of molecular medicine · 2025Review
- Targeting ferroptosis with natural products in stroke: therapeutic mechanisms and translational opportunities.Frontiers in pharmacology · 2025Review
- A nested case-control study investigating short-term prognosis, clinical and imaging features in acute ischemic stroke patients with systemic lupus erythematosus.Acta neurologica Belgica · 2023Article
- Observational
- The Predictive Value of Contrast-Enhanced Ultrasound Combined with Serum miR-124 Level in Acute Cerebral Infarction and Their Correlation with the Contrast Enhancement of Carotid Atherosclerotic Plaque.Neuropsychiatric disease and treatment · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the changes and significance of serum CXC chemokine ligand 16 (CXCL-16), growth differentiation factor 15 (GDF-15) and lipoprotein-related phospholipase A2 (PLA-2) levels in patients with cerebral infarction.
methodsA total of 87 patients with cerebral infarction between August 2019 and May 2020 in our hospital were selected as the disease group, and 50 healthy patients were selected as the healthy control group. Enzyme-linked immunosorbent assay was used to detect serum CXCL-16, GDF-15, PLA-2 expression levels in all subjects. A comprehensive evaluation was made in terms of changes of various indicator levels in patients while the changes of CXCL-16, GDF-15, PLA-2 in patients with cerebral infarction after effective treatment were monitored.
resultsCompared with the healthy group, the expression levels of serum CXCL-16, GDF-15 and PLA-2 in the disease group were up-regulated (
conclusionSerum CXCL-16, GDF-15, PLA-2 in patients with cerebral infarction were all highly expressed and changed with the disease severity, which can be used as reliable indicators for monitoring the incidence, severity, and prognosis of cerebral infarction.
Indexed as
Identifiers
34150166PMC8205804W3175213491What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.